Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Myasthenia Gravis Drugs Market by Type (Anticholinesterases, Immunosuppressants, Intravenous Immune Globulins), By Application (Hospitals, Clinics) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Myasthenia Gravis Drugs Market by Type (Anticholinesterases, Immunosuppressants, Intravenous Immune Globulins), By Application (Hospitals, Clinics) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 202811 3300 Pharma & Healthcare 377 241 Pages 4.8 (42)
                                          

The global myasthenia gravis drugs market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 1.2 billion by 2030. The growth of this market is driven by the increasing prevalence of myasthenia gravis and the introduction of new drugs in the market. Anticholinesterases are expected to be the fastest-growing segment in this market, with a CAGR of 6.8%. This growth can be attributed to their efficacy and safety profile as well as their low cost per dose, which makes them an attractive option for patients with mild or moderate symptoms who do not require immunosuppressants or intravenous immune globulins (IVIG). Anticholinesterases are also used for treating other conditions such as Alzheimer's disease and Parkinson's disease, which will drive their demand over the next few years. North America is expected to dominate this market during the forecast period due to its high prevalence rate and availability of advanced healthcare facilities that offer treatment options for myasthenia gravis patients such as IVIGs and immunosuppressants that are not available in other regions such as Latin America, Europe, Asia Pacific, Middle East & Africa (MEA).

Some Of The Growth Factors Of This Market:

  1. Increasing prevalence of autoimmune disorders, such as myasthenia gravis, is one of the major factors driving the growth of this market.
  2. Increasing number of clinical trials for new drugs in this segment is also expected to fuel the growth of this market during the forecast period.
  3. Growing geriatric population and increasing incidence rates are some other factors that are expected to drive the growth of this market during the forecast period.
  4. Lack of awareness about myasthenia gravis and its treatment options among patients and healthcare providers is one factor that may hinder the growth rate in near future.

Industry Growth Insights published a new data on “Myasthenia Gravis Drugs Market”. The research report is titled “Myasthenia Gravis Drugs Market research by Types (Anticholinesterases, Immunosuppressants, Intravenous Immune Globulins), By Applications (Hospitals, Clinics), By Players/Companies Flamel Technologies, Roche, Grifols, Pfizer, Shire, Novartis, Valeant, Alexion, Catalyst, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Myasthenia Gravis Drugs Market Research Report

By Type

Anticholinesterases, Immunosuppressants, Intravenous Immune Globulins

By Application

Hospitals, Clinics

By Companies

Flamel Technologies, Roche, Grifols, Pfizer, Shire, Novartis, Valeant, Alexion, Catalyst, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

241

Number of Tables & Figures

169

Customization Available

Yes, the report can be customized as per your need.


Global Myasthenia Gravis Drugs Industry Outlook


Global Myasthenia Gravis Drugs Market Report Segments:

The global Myasthenia Gravis Drugs market is segmented on the basis of:

Types

Anticholinesterases, Immunosuppressants, Intravenous Immune Globulins

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospitals, Clinics

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Flamel Technologies
  2. Roche
  3. Grifols
  4. Pfizer
  5. Shire
  6. Novartis
  7. Valeant
  8. Alexion
  9. Catalyst
  10. CSL
  11. Curavac
  12. Cytokinetics
  13. Galencia
  14. GlaxoSmithKline
  15. Lupin Pharmaceuticals
  16. Mitsubishi Tanabe Pharma

Global Myasthenia Gravis Drugs Market Overview


Highlights of The Myasthenia Gravis Drugs Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Anticholinesterases
    2. Immunosuppressants
    3. Intravenous Immune Globulins
  1. By Application:

    1. Hospitals
    2. Clinics
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Myasthenia Gravis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Myasthenia Gravis Drugs Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Myasthenia gravis (MG) is a neuromuscular disorder that affects the ability of the muscles to contract. MG can be caused by a number of factors, including an autoimmune response or viral infection. Drugs used to treat MG include acetylcholinesterase inhibitors (AChEIs), which block the action of acetylcholine, and muscle relaxants.

Some of the major players in the myasthenia gravis drugs market are Flamel Technologies, Roche, Grifols, Pfizer, Shire, Novartis, Valeant, Alexion, Catalyst, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma.

The myasthenia gravis drugs market is expected to register a CAGR of 5.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Myasthenia Gravis Drugs Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Myasthenia Gravis Drugs Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Myasthenia Gravis Drugs Market - Supply Chain
   4.5. Global Myasthenia Gravis Drugs Market Forecast
      4.5.1. Myasthenia Gravis Drugs Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Myasthenia Gravis Drugs Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Myasthenia Gravis Drugs Market Absolute $ Opportunity

5. Global Myasthenia Gravis Drugs Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Myasthenia Gravis Drugs Market Size and Volume Forecast by Type
      5.3.1. Anticholinesterases
      5.3.2. Immunosuppressants
      5.3.3. Intravenous Immune Globulins
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Myasthenia Gravis Drugs Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Myasthenia Gravis Drugs Market Size and Volume Forecast by Application
      6.3.1. Hospitals
      6.3.2. Clinics
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Myasthenia Gravis Drugs Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Myasthenia Gravis Drugs Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Myasthenia Gravis Drugs Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Myasthenia Gravis Drugs Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Myasthenia Gravis Drugs Demand Share Forecast, 2019-2026

9. North America Myasthenia Gravis Drugs Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Myasthenia Gravis Drugs Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Myasthenia Gravis Drugs Market Size and Volume Forecast by Application
      9.4.1. Hospitals
      9.4.2. Clinics
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Myasthenia Gravis Drugs Market Size and Volume Forecast by Type
      9.7.1. Anticholinesterases
      9.7.2. Immunosuppressants
      9.7.3. Intravenous Immune Globulins
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Myasthenia Gravis Drugs Demand Share Forecast, 2019-2026

10. Latin America Myasthenia Gravis Drugs Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Myasthenia Gravis Drugs Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Myasthenia Gravis Drugs Market Size and Volume Forecast by Application
      10.4.1. Hospitals
      10.4.2. Clinics
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Myasthenia Gravis Drugs Market Size and Volume Forecast by Type
      10.7.1. Anticholinesterases
      10.7.2. Immunosuppressants
      10.7.3. Intravenous Immune Globulins
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Myasthenia Gravis Drugs Demand Share Forecast, 2019-2026

11. Europe Myasthenia Gravis Drugs Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Myasthenia Gravis Drugs Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Myasthenia Gravis Drugs Market Size and Volume Forecast by Application
      11.4.1. Hospitals
      11.4.2. Clinics
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Myasthenia Gravis Drugs Market Size and Volume Forecast by Type
      11.7.1. Anticholinesterases
      11.7.2. Immunosuppressants
      11.7.3. Intravenous Immune Globulins
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Myasthenia Gravis Drugs Demand Share, 2019-2026

12. Asia Pacific Myasthenia Gravis Drugs Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Myasthenia Gravis Drugs Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Myasthenia Gravis Drugs Market Size and Volume Forecast by Application
      12.4.1. Hospitals
      12.4.2. Clinics
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Myasthenia Gravis Drugs Market Size and Volume Forecast by Type
      12.7.1. Anticholinesterases
      12.7.2. Immunosuppressants
      12.7.3. Intravenous Immune Globulins
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Myasthenia Gravis Drugs Demand Share, 2019-2026

13. Middle East & Africa Myasthenia Gravis Drugs Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Myasthenia Gravis Drugs Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Myasthenia Gravis Drugs Market Size and Volume Forecast by Application
      13.4.1. Hospitals
      13.4.2. Clinics
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Myasthenia Gravis Drugs Market Size and Volume Forecast by Type
      13.7.1. Anticholinesterases
      13.7.2. Immunosuppressants
      13.7.3. Intravenous Immune Globulins
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Myasthenia Gravis Drugs Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Myasthenia Gravis Drugs Market: Market Share Analysis
   14.2. Myasthenia Gravis Drugs Distributors and Customers
   14.3. Myasthenia Gravis Drugs Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Flamel Technologies
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Roche
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Grifols
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Pfizer
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Shire
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Novartis
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Valeant
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Alexion
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Catalyst
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. CSL
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Curavac
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Cytokinetics
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. Galencia
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. GlaxoSmithKline
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. Lupin Pharmaceuticals
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. Mitsubishi Tanabe Pharma
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us